New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2014
17:52 EDTJNJ, CAPRCapricor gets $12.5M upfront payment in Janssen development agreement
Capricor Therapeutics (CAPR) disclosed in a regulatory filing that it entered into a collaboration agreement and with Janssen Biotech, a wholly-owned subsidiary of Johnson & Johnson (JNJ). Under the terms of the agreement, Capricor and Janssen agreed to collaborate on the development of Capricorís cell therapy program for cardiovascular applications, including its lead product, CAP-1002. Capricor and Janssen further agreed to collaborate on the development of cell manufacturing in preparation for future clinical trials. Under the agreement, Capricor will receive an upfront cash payment of $12.5M from Janssen, and Capricor will also contribute to the costs of development of a chemistry, manufacturing and controls package. In addition, Janssen will have the exclusive right to enter into an exclusive license agreement pursuant to which Janssen would receive a worldwide, exclusive license to exploit CAP-1002 as well as certain allogeneic cardiospheres and cardiosphere-derived cells in the field of cardiology. Janssen has the right to exercise the option at any time until sixty days after the delivery by Capricor of the six-month follow-up results from Phase II of Capricorís ALLSTAR clinical trial for CAP-1002. If Janssen exercises its option rights, Capricor would receive an upfront license fee and additional milestone payments which may total up to $325M. In addition, a double-digit royalty would be paid on commercial sales of licensed products
News For CAPR;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 23, 2015
06:08 EDTCAPRBioLife Solutions, Capricor provide update on CAP-1002 DYNAMIC clinical trial
Subscribe for More Information
November 20, 2015
10:52 EDTJNJFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information
November 18, 2015
08:11 EDTJNJIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
08:11 EDTJNJAduro Biotech receives milestone payment from Janssen
Aduro Biotech (ADRO) announced that it has received a milestone payment from Janssen Biotech (JNJ) for Aduro's submission of an Investigational New Drug, or IND, Application to the FDA for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. The IND will enable Janssen, Aduro's license partner for ADU-741, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 in patients with metastatic castration-resistant prostate cancer.
November 16, 2015
14:38 EDTJNJGenmab confirms FDA approval of Darzalex
Subscribe for More Information
13:09 EDTJNJFDA approves Darzalex to treat multiple myeloma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use